Clinical Trial Detail

NCT ID NCT03755791
Title Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications

hepatocellular carcinoma

Therapies

Cabozantinib

Sorafenib

Atezolizumab + Cabozantinib

Age Groups: senior adult

No variant requirements are available.